Tempus ECG-Low EF vs AVIEW
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary objective is to rapidly screen patients aged 40 or older for signs associated with low left ventricular ejection fraction (LVEF ≤40%) using routine 12-lead ECG recordings. This tool is ideal for early identification of individuals at risk of heart failure in settings like emergency medicine or internal medicine, where a quick, non-invasive indicator can guide further diagnostic evaluation, such as an echocardiogram.
View Tempus ECG-Low EF →Choose AVIEW if…
Choose AVIEW if you require a comprehensive AI platform for detailed analysis of CT scans across multiple cardiopulmonary conditions, including lung cancer screening, COPD quantification, and coronary artery calcification scoring. This solution is best suited for radiology departments and specialists seeking advanced quantification, 3D visualizations, and workflow automation to enhance diagnostic precision and monitoring capabilities for complex cases.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | AVIEW |
|---|---|---|
| Pricing | Unknown | Subscription; one-off payment |
| Deployment | Integrates with current ECG platforms and electronic health records (EHRs). | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-Low EFTool A provides a binary output (Low LVEF Detected / Not Detected) and integrates into existing healthcare facility workflows, suggesting a highly straightforward and easy-to-interpret result for clinicians. While Tool B offers comprehensive features and integration, the simplicity of Tool A's output minimizes cognitive load for its specific diagnostic aid.
Clinical Value
AVIEWBoth tools are FDA-cleared, indicating validated clinical utility. However, Tool B offers a broader and deeper clinical impact by providing comprehensive solutions for the early detection, diagnosis, and monitoring of multiple critical conditions (lung cancer, COPD, and coronary artery calcification) from CT scans, including detailed quantification and risk stratification. Tool A, while valuable, focuses on a single cardiac risk factor from ECGs.
Pricing & Value
AVIEWTool B offers more transparent pricing models, including subscription and one-off payment options based on installations or users, providing potential buyers with clearer upfront information. In contrast, Tool A's 'contact vendor' approach offers no public insight into its pricing structure, making it harder to assess initial value without direct engagement.
Enterprise Readiness
AVIEWBoth tools are HIPAA compliant and FDA cleared, establishing a strong foundation for enterprise use. However, Tool B offers significantly more flexible deployment options, including cloud-based, hybrid, locally on dedicated hardware, and locally virtualized solutions, which caters to a wider range of enterprise IT infrastructures and security requirements.
Innovation
AVIEWWhile Tool A's application of AI to readily available ECGs for LVEF detection is innovative, Tool B demonstrates broader and deeper innovation through its comprehensive, multi-disease platform for CT scans. Its advanced capabilities include automated segmentation, 3D visualizations, detailed quantification, and follow-up tracking across several complex conditions.
Support & Docs
AVIEWCoreline Soft provides a dedicated customer service email and readily available technical documentation and catalogs for its AVIEW products, indicating a more structured and accessible support framework. For Tempus ECG-Low EF, specific public support channels or detailed documentation beyond product descriptions are not easily identifiable through general web searches.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | AVIEW |
|---|---|---|
| Name | Tempus ECG-Low EF | AVIEW |
| Company | Tempus AI | Coreline Soft Co. |
| Description | Tempus ECG-Low EF is an FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. | Coreline Soft's AVIEW AI platform offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows. |
| Primary Focus | Detection of low Left Ventricular Ejection Fraction (LVEF u226440%) from ECGs | Early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and AVIEW.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-Low EF or AVIEW
Backers
Who funded each tool's parent company.